Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NANONC

Financiado

Cerrado

Nanomaterials in Oncology Exploiting the Intrinsic Cancer Specific Toxicity of...

Nanomaterials in Oncology Exploiting the Intrinsic Cancer Specific Toxicity of Nanoparticles. In our current society, therapeutic strategies against cancer suffer from dose-limiting toxicity, lack of specificity and high morbidity. To overcome this, the use of nanomaterials (NMs) is rising, where several NM formulations ar... ver más

31/12/2022

KU Leuven

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-12-31

ERC-2017-STG: ERC Starting Grant

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

KU Leuven

1.95M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-118448RB-C22 DESARROLLO DE NANOSISTEMAS MULTIFUNCIONALES BASADOS EN METAL... 121K€ Cerrado

HybridNP Remotely actuated re-shaped nanocarriers for tumour targetin... 150K€ Cerrado

NANOTECHNOLOGYMETAST TREATING METASTATIC CANCER WITH NANOTECHNOLOGY 100K€ Cerrado

CTQ2014-54761-R DESARROLLO DE NANOMATERIALES QUIMIOINMUNOTERAPEUTICOS PARA E... 178K€ Cerrado

NANOTHER Integration of Novel Nanoparticle based Technology for Thera... 12M€ Cerrado

CTQ2008-03739 NANOPARTICULAS MAGNETICAS MULTIFUNCIONALES PARA LA LIBERACIO... 91K€ Cerrado

Duración del proyecto: 63 meses Fecha Inicio: 2017-09-25
Fecha Fin: 2022-12-31

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In our current society, therapeutic strategies against cancer suffer from dose-limiting toxicity, lack of specificity and high morbidity. To overcome this, the use of nanomaterials (NMs) is rising, where several NM formulations are undergoing clinical trials or are used in clinics where the NMs are used as drug delivery vehicles or as mediators in physical anticancer methods (e.g. hyperthermia), where to date, the success rate is limited due to low tumor targeting efficacy, lack of specificity and frequent re-use of classical toxicity mechanisms. To overcome these issues, this research program aims to exploit the intrinsic toxicity of certain types of metal-based, degradation-prone NMs (Fe-doped ZnO, Fe-doped CuO and Ag of different sizes and coatings) towards only cancer cells as a novel and generic anti-cancer tool with 1) improved efficacy against difficult to treat cancers such as multidrug-resistant cancer cells, 2) enhanced specificity and selectivity of the treatment by the intrinsic cancer cell-specific toxicity of NMs towards cancer cells. To overcome the issues related to selective delivery of the NMs, tumor-homing cells will be used that have been shown to efficiently home to primary tumors and their metastases. In practice, the NMs used show distinct degradation kinetics that primarily induce cancer-selective toxicity. To obtain efficient tumor targeting, suicide gene-expressing tumor-homing cells will be loaded with the NMs in their cytoplasm, hereby impeding premature NM degradation. The tumor homing efficacy of these cells will be monitored via optical imaging and once at the target site these cells will be chemically destroyed using the suicide gene strategy. This will release the NMs into the tumor site, where they can selectively destroy the cancer cells. This research program will be the first to explore the full potential of cancer-specific toxicity of NMs and the use of cytoplasmic loading of cells as biological carriers for efficient delivery.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores